By Associate Professor Liz Caldon

Journal articles

Caldon CE, 2014, 'Estrogen signaling and the dna damage response in hormone dependent breast cancers', Frontiers in Oncology, 4 MAY, http://dx.doi.org/10.3389/fonc.2014.00106

Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JMW; Nicholson RI; Print CG; Clark SJ; Musgrove EA, 2013, 'BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer', Molecular Cancer Therapeutics, 12, pp. 1874 - 1885, http://dx.doi.org/10.1158/1535-7163.MCT-13-0012

Ortiz-Padilla C; Gallego-Ortega D; Browne BC; Hochgräfe F; Caldon CE; Lyons RJ; Croucher DR; Rickwood D; Ormandy CJ; Brummer T; Daly RJ, 2013, 'Functional characterization of cancer-associated Gab1 mutations.', Oncogene, 32, pp. 2696 - 2702, http://dx.doi.org/10.1038/onc.2012.271

Caldon CE; Sergio CM; Burgess A; Deans AJ; Sutherland RL; Musgrove EA, 2013, 'Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1', Cell Cycle, 12, pp. 606 - 617, http://dx.doi.org/10.4161/cc.23512

Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA, 2012, 'Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells', MOLECULAR CANCER THERAPEUTICS, 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963

Caldon CE; Sergio CM; Kang JW; Muthukaruppan A; Boersma M; Stone A; Barraclough J; Lee CS; Black MJ; Miller LA; Gee JMW; Robert i nicholson RI; Sutherland RL; Print C; Musgrove EA, 2012, 'Cyclin E2 overexpression is associated with endocrine resistance but not insensivity to CDK2 inhibition in human breast cancer cells', Molecular Cancer Therapeutics, 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963

Kalyuga M; Gallego-Ortega D; Lee HJ; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Launchbury R; Statham AL; Armstrong N; Alles MC; Young A; Egger A; Au W; Piggin CL; Evans CJ; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JMW; Nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ, 2012, 'ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.', PLoS Biol, 10, pp. e1001461, http://dx.doi.org/10.1371/journal.pbio.1001461

Musgrove EA; Caldon CE; Barraclough J; Stone A; Sutherland RL, 2011, 'Cyclin D as a therapeutic target in cancer', Nature Reviews Cancer, 11, pp. 558 - 572, http://dx.doi.org/10.1038/nrc3090

Caldon CE; Sergio CM; Schutte J; Boersma M; Sutherland RL; Carroll J; Musgrove EA, 2009, 'Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc', Molecular and Cellular Biology, 29, pp. 4623 - 4639

Butt A; Caldon CE; Mcneil CM; Swarbrick A; Musgrove EA; Sutherland RL, 2008, 'Cell cycle machinery: Links with genesis and treatment of breast cancer', Advances in Experimental Medicine and Biology, 630, pp. 189 - 205

Musgrove EA; Sergio CM; Loi S; Inman CK; Anderson LR; Alles MC; Pinese M; Caldon CE; Schutte J; Gardiner-Garden M; Ormandy CJ; McArthur G; Butt A; Sutherland RL, 2008, 'Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer', PLoS One, 3, pp. 2987 - 2995

Caldon CE; Swarbrick A; Lee CS; Sutherland RL; Musgrove EA, 2008, 'The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini', Cancer research, 68, pp. 3026 - 3036, http://dx.doi.org/10.1158/0008-5472.CAN-07-3079

Caldon CE; Lee CS; Sutherland RL; Musgrove EA, 2008, 'Wilms` tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation', Oncogene, 27, pp. 126 - 138, http://dx.doi.org/10.1038/sj.onc.1210622

Caldon CE; Daly RJ; Sutherland RL; Musgrove EA, 2006, 'Cell cycle control in breast cancer cells.', J Cell Biochem, 97, pp. 261 - 274, http://dx.doi.org/10.1002/jcb.20690

Brummer T; Schramek D; Hayes VM; Bennett HL; Caldon CE; Musgrove EA; Daly RJ, 2006, 'Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein.', J Biol Chem, 281, pp. 626 - 637, http://dx.doi.org/10.1074/jbc.M509567200

Swarbrick A; Akerfeldt M; Lee CS; Sergio CM; Caldon CE; Hunter LJ; Sutherland RL; Musgrove EA; Lee CS, 2005, 'Regulation of cyclin expression and cell cycle progression in breastepithelial cells by the helix-loop-helix protein Id1', Oncogene, 24, pp. 381 - 389

Nadkarni MA; Caldon CE; Chhour KL; Fisher IP; Martin FE; Jacques NA; Hunter N, 2004, 'Carious dentine provides a habitat for a complex array of novel Prevotella-like bacteria', Journal of Clinical Microbiology, 42, pp. 5238 - 5244, http://dx.doi.org/10.1128/JCM.42.11.5238-5244.2004

Kus BM; Caldon CE; Andorn-Broza R; Edwards AM, 2004, 'Functional Interaction of 13 Yeast SCF Complexes with a Set of Yeast E2 Enzymes In Vitro', Proteins Structure Function and Genetics, 54, pp. 455 - 467, http://dx.doi.org/10.1002/prot.10620

Paramaesvaran M; Caldon E; Najdi S; Gonzaga G; Hunter N; Nguyen K; McDonald J; Langley DB; Crossley MJ; Collyer CA; Esvaran M, 2003, 'Porphyrin-mediated Cell Surface Heme Capture from Hemoglobin by Porphyromonas gingivalis.', Journal of Bacteriology, 185, pp. 2528 - 2537, http://dx.doi.org/10.1128/JB.185.8.2528-2537.2003

March PE, 2001, 'Evolution of a molecular switch;universal bacterial GTPases regulate ribosome function', Molecular Microbiology, pp. 289 - 297

Conference Papers

O'Toole S; Swarbrick A; Millar E; McLeod D; McNeil C; Qiu MR; Lopez-Knowles E; Caldon E; Oakes S; Ormandy C; Morey A; Musgrove E; Henshall S; Sutherland R, 2008, 'Aberrent hedgehog signaling is an early event in breast cancer development', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, pp. 70S - 70S, presented at 31st Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 10 December 2008 - 14 December 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000262583200031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kus B; Caldon C; Edwards A, 2003, 'Proteome-wide biochemical screen to identify ubiquitination targets of yeast ubiquitin ligase enzymes', in YEAST, JOHN WILEY & SONS LTD, SWEDEN, GOTHENBURG, pp. S151 - S151, presented at 21st International Conference on Yeast Genetics and Molecular Biology, SWEDEN, GOTHENBURG, 07 July 2003 - 12 July 2003, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000184161800341&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Presentations

Portman N; Milioli HH; Alexandrou S; Coulson R; Young A; Chia KM; Haup S; Haup Y; Caldon L; Lim E, 2019, 'The MDM2 inhibitor NVP-CGM097 synergises with fulvestrant and inhibits Estrogen Receptor positive breast cancer', presented at Hormone-Dependent Cancers (GRS), Newry, USA

Conference Abstracts

Phan Z; Ford CE; Caldon E, 2024, 'Abstract A115: DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. a115 - a115, http://dx.doi.org/10.1158/1538-7445.ovarian23-a115

Freelander A; Laven-Law G; Eshraghi L; Geetha N; Somerville P; Pickering M; Alexandrou S; Caldon CE; Tilley WD; Hickey TE; Lim E, 2022, 'Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER plus AR plus breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 83, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2022 - 10 December 2022, http://dx.doi.org/10.1158/1538-7445.SABCS22-P4-08-16

Freelander A; Laven-Law G; Eshraghi L; Chia KM; Pickering M; Yong A; Wilkinson A; Alexandrou S; Caldon CE; Hickey TE; Tilley WD; Lim E, 2022, 'Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. pd2-02-pd2-02, http://dx.doi.org/10.1158/1538-7445.sabcs21-pd2-02

Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982

Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03

Aziz D; Lee C; Chin V; Fernandez K; Etemadmoghadam D; Bowtell D; Waring PM; Caldon CE, 2019, 'Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700245&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043

Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001

Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012

Whittle JR; Vaillant F; Policheni AN; Liu K; Pal B; Giner G; Fernandez K; Gray DH; Caldon CE; Smyth GK; Visvader JE; Lindeman GJ, 2018, 'Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-PD7-07

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017

Working Papers

Du Q; Smith GC; Luu PL; Ferguson JM; Armstrong NJ; Caldon CE; Campbell E; Nair SS; Zotenko E; Gould CM; Buckley M; Kaczorowski D; Barton K; Deveson IW; Smith MA; Powell JE; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark SJ, DNA methylation is required to maintain DNA replication timing precision and 3D genome integrity, Cold Spring Harbor Laboratory, http://dx.doi.org10.1101/2020.10.15.338855

Preprints

Caldon C; Alexandrou S; Lee C; Fernandez K; Wiharja C; Eshraghi L; Reeves J; Reed D; Portman N; Phan Z; Milioli H; Nikolic I; Cadell A; Croucher D; Simpson K; Lim E; Hickey T; Millar E; Alves C; Ditzel H, 2025, JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, http://dx.doi.org/10.21203/rs.3.rs-5920749/v1

Du Q; Bert S; Armstrong N; Caldon E; Song J; Nair S; Gould C; Luu PL; Khoury A; Qu W; Zotenko E; Stirzaker C; Clark S, 2018, Replication timing shapes the cancer epigenome and the nature of chromosomal rearrangements, http://dx.doi.org/10.1101/251280

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, http://dx.doi.org/10.1101/2020.01.29.911883

Phan Z; Ford CE; Caldon CE, DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review, http://dx.doi.org/10.1101/2023.05.24.23290442

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer, http://dx.doi.org/10.1101/2020.06.09.140921

Hosseinpour M; Malaver-Ortega L; Perlaza-Jimenez L; Joo JE; Liu L; Caldon EC; Dugué P-A; Dowty JG; Southey MC; Rosenbluh J, SAM-DNMT3A, a strategy for induction of genome-wide DNA methylation, identifies DNA methylation as a vulnerability in ER-positive breast cancers, http://dx.doi.org/10.1101/2024.01.16.575955

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Phan Z; Fernandez KJ; Caldon CE, Unmatched cell line collections are not optimal for identification of PARP inhibitor response and drug synergies, http://dx.doi.org/10.1101/2025.04.28.650908

Back to profile page